Compugen Ltd (Compugen) is a clinical-stage drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s pipeline comprises COM701 and PVRIG, BAY 1905254, COM902, and TIGIT. Its drug development process includes target discovery, target validation and predictive discovery programs. Compugen drug programs finds therapies to treat metastatic microsatellite stable colorectal cancer, platinum resistant ovarian cancer, advanced and metastatic non-small cell lung cancer (NSCLC) and metastatic gastric cancer. It operates in Israel, the US and Canada. Compugen is headquartered in Holon, Tel Aviv, Israel.
Headquarters
Israel
Address
Azrieli Center, 26 Harokmim St. Bldg D, Holon, Sharon (Netanya), 5885849
Website
cgen.com
Telephone
972 3 7658585
No of Employees
68
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CGEN (TLV)
Revenue (2022)
$33.5M
346.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
44.3%
(2022 vs 2021)
Market Cap*
$170.1M
Net Profit Margin (2022)
XYZ
87.5%
(2022 vs 2021)
* As of and is in US$
Compugen Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| COM701 and COM902: |
| Metastatic Microsatellite Stable Colorectal Cancer and Platinum Resistant Ovarian Cancer |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company and Gilead Sciences entered into an agreement, under the agreement Gilead Sciences will obtain a license for Compugen's pre-clinical antibody program targeting IL-18 binding protein. |
| 2023 | Corporate Changes/Expansions | In June, Compugen's COM701 (anti-PVRIG) demonstrated its preliminary durable anti-tumor activity in triple immunotherapy with combination of recurrent metastatic MSS endometrial cancer. |
| 2021 | Financing Agreements | In November, the company secured US$20 million investment from Bristol Myers Squibb. |
Competitor Comparison
| Key Parameters | Compugen Ltd | BioLineRx Ltd | Biond Biologics Ltd | Glycominds Ltd. | Indaptus Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | Israel | Israel | Israel | Israel | United States of America |
| City | Holon | Modiin | Nahariya | Ra'Anana | New York |
| State/Province | Sharon (Netanya) | - | Jezreel Valley | - | New York |
| No. of Employees | 68 | 49 | - | - | 7 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul Sekhri | Chairman | Executive Board | 2017 | 64 |
| Anat Cohen-Dayag, Ph.D. | President; Director; Chief Executive Officer | Executive Board | 2010 | 56 |
| Alberto Sessa | Chief Financial Officer | Senior Management | 2022 | - |
| Michelle Mahler, M.D. | Chief Medical Officer | Senior Management | 2024 | - |
| Eran Ophir, Ph.D | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward